{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:58:43Z","timestamp":1773061123056,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Adult T\u2010cell leukemia\u2010lymphoma (ATL) is a rare, aggressive malignancy prevalent in Japan, the Caribbean, and Central\/South America. This multicenter retrospective study evaluated the effectiveness and safety of brentuximab vedotin with cyclophosphamide, doxorubicin, and prednisolone (BV\u2010CHP) in patients aged \u2265\u00a018\u00a0years with previously untreated CD30\u2010positive ATL, verified through immunohistochemistry\/flow cytometry, from six hospitals in Japan. Outcomes included overall response rate (ORR; primary outcome), overall survival (OS), progression\u2010free survival (PFS), complete response rate (CRR), disease control rate (DCR), and safety. Subgroup analyses evaluated lesion site, ATL subtype, age, and CD30 expression. Of 46 screened patients, 36 (median age 71\u00a0years; 66.7% female) were analyzed and started BV\u2010CHP between April 2020 and January 2024. CD30 positivity was confirmed in all patients. ORR was 86.1% (95% confidence interval [CI] 70.5\u201395.3), CRR 61.1% (95% CI 43.5\u201376.9), and DCR 91.7% (95% CI 77.5\u201398.3). ORR by lesion site (lymph nodes, peripheral blood, skin) was 93.8%, 90.9%, and 83.3%, respectively, by ATL subtype (acute, lymphoma) was 78.9% and 94.1%, respectively, and by age (\u2264\u00a070\u00a0years, &gt;\u00a070\u00a0years) was 84.6% and 87.0%, respectively. One patient with CD30 expression &lt;\u00a010% achieved a complete response; ORR was 73.7% in 19 patients with CD30 expression \u2265\u00a010%. Median OS and PFS was 535\u00a0days (95% CI 343\u2013not estimable) and 205\u00a0days (95% CI 166\u2013279), respectively. Treatment\u2010emergent adverse events of any grade and grade \u2265\u00a03 both occurred in 88.9% of patients, with neutropenia, febrile neutropenia, and thrombocytopenia being most common. Among 11 patients who underwent allogeneic stem cell transplantation, two developed acute graft\u2010versus\u2010host disease; median PFS was 234\u00a0days (95% CI 168\u2013343), compared with 180\u00a0days (95% CI 96\u2013279) without transplantation. BV\u2010CHP demonstrated high ORR and CRR across age groups and ATL subtypes with a manageable safety profile, supporting its potential use as a standard treatment option.<\/jats:p>","DOI":"10.1002\/hon.70141","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:18:56Z","timestamp":1761070736000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Multicenter Real\u2010World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30\u2010Positive Adult T\u2010Cell Leukemia\u2010Lymphoma"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-9006","authenticated-orcid":false,"given":"Masahito","family":"Tokunaga","sequence":"first","affiliation":[{"name":"Department of Hematology Imamura General Hospital  Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-2920","authenticated-orcid":false,"given":"Junya","family":"Makiyama","sequence":"additional","affiliation":[{"name":"Department of Hematology Sasebo City General Hospital  Sasebo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0403-0122","authenticated-orcid":false,"given":"Motoaki","family":"Shiratsuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology Iizuka Hospital  Iizuka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Toyama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Miyazaki Prefectural Nobeoka Hospital  Nobeoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Blood Transfusion Kochi Health Sciences Center  Kochi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-7045","authenticated-orcid":false,"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy NHO Kyushu Cancer Center  Fukuoka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Japan Medical Affairs Japan Oncology Business Unit Takeda Pharmaceutical Company Limited  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-8872","authenticated-orcid":false,"given":"Kiyoshi","family":"Okazuka","sequence":"additional","affiliation":[{"name":"Japan Medical Affairs Japan Oncology Business Unit Takeda Pharmaceutical Company Limited  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8843-406X","authenticated-orcid":false,"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology Imamura General Hospital  Kagoshima Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v50.3.481.bloodjournal503481"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.6.2031"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010022\u201001620\u20102"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2428"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01124"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00501"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00388"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1993.9.381"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28606"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.17479.1"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010018\u20105209\u20105"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102141.1991.tb08051.x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102015\u201003\u2010632489"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14658"},{"key":"e_1_2_12_16_1","volume-title":"Chemotherapy of ATL","author":"Shimoyama M.","year":"1994"},{"key":"e_1_2_12_17_1","unstructured":"S. M.Horwitz S.Ansell W. Z.Ai et\u00a0al. \u201cNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): T\u2010Cell Lymphomas Version 1.2025 \u201d accessed November 28 2024 https:\/\/www.nccn.org\/guidelines\/guidelines\u2010detail?category=1&id=1483."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.0669"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9958"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010024\u201003836\u20107"},{"issue":"10","key":"e_1_2_12_21_1","first-page":"3625","article-title":"Clinical Significance of CCR4 Expression in Adult T\u2010cell Leukemia\/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome","volume":"9","author":"Ishida T.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13338"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027902"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)32984\u20102"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1990.8.12.1935"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.2101"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185\u2010018\u201002588\u20105"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00084"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004045"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010173822"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.3969"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac137"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.198"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100967"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102012\u201003\u2010414490"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9082417"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.8250"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15152"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70141","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.70141","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.70141","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:49:41Z","timestamp":1773049781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.70141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1002\/hon.70141"],"URL":"https:\/\/doi.org\/10.1002\/hon.70141","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"2025-03-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70141"}}